Renaissance Technologies's CNTA Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 279,300 shares of Centessa Pharmaceuticals plc (CNTA) worth $6.99 M, representing 0.01% of the portfolio. First purchased in 2023-Q1, this medium-term investment has been held for 12 quarters.
Based on 13F filings, Renaissance Technologies has maintained a strategic position in CNTA, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 206,900 shares. Largest reduction occurred in Q3 2025, reducing 220,300 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Centessa Pharmaceuticals plc (CNTA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Centessa Pharmaceuticals plc (CNTA) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +114,700 | Add 69.68% | 279,300 | $25.01 |
| Q3 2025 | -220,300 | Reduce 57.24% | 164,600 | $24.25 |
| Q2 2025 | +206,900 | Add 116.24% | 384,900 | $13.14 |
| Q1 2025 | -600 | Reduce 0.34% | 178,000 | $14.38 |
| Q4 2024 | -31,000 | Reduce 14.79% | 178,600 | $16.75 |
| Q3 2024 | +35,900 | Add 20.67% | 209,600 | $15.99 |
| Q2 2024 | -45,100 | Reduce 20.61% | 173,700 | $9.03 |
| Q1 2024 | +33,200 | Add 17.89% | 218,800 | $11.30 |
| Q4 2023 | +132,500 | Add 249.53% | 185,600 | $7.96 |
| Q3 2023 | +18,800 | Add 54.81% | 53,100 | $6.48 |
| Q2 2023 | +18,600 | Add 118.47% | 34,300 | $0.01 |
| Q1 2023 | +15,700 | New Buy | 15,700 | $0.00 |
Renaissance Technologies's Centessa Pharmaceuticals plc Investment FAQs
Renaissance Technologies first purchased Centessa Pharmaceuticals plc (CNTA) in Q1 2023, acquiring 15,700 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Centessa Pharmaceuticals plc (CNTA) for 12 quarters since Q1 2023.
Renaissance Technologies's largest addition to Centessa Pharmaceuticals plc (CNTA) was in Q2 2025, adding 384,900 shares worth $5.06 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 279,300 shares of Centessa Pharmaceuticals plc (CNTA), valued at approximately $6.99 M.
As of the Q4 2025 filing, Centessa Pharmaceuticals plc (CNTA) represents approximately 0.01% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in Centessa Pharmaceuticals plc (CNTA) was 384,900 shares, as reported at the end of Q2 2025.